Designer Receptors Exclusively Activated By Designer Drugs (Dreadd) Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DREADD-expressing neurons are used in research to manipulate neural circuits in neurodegenerative disease models. [@chemogenetics2020]
Overview
DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) are chemogenetic tools based on G-protein coupled receptors.
For researchers considering [DREADDs](/technologies/dreadds) vs. other methods:
Clinical Translation
DREADDs are primarily research tools. Similar chemogenetic approaches may eventually translate to clinical applications via [AAV gene therapy](/therapeutics/aav-gene-therapy-neurodegeneration).
Molecular Mechanisms
Receptor Activation Pathways
DREADDs exploit the [muscarinic acetylcholine receptor](/proteins/chrm4-protein) signaling pathway:
hM3Dq (Gq-DREADD): Activates Gq proteins, leading to [phospholipase C](/proteins/plc-protein) (PLC) activation, IP3 production, and [calcium release](/mechanisms/calcium-dysregulation-alzheimers) from intracellular stores. This results in neuronal excitation.
hM4Di (Gi-DREADD): Inhibits [adenylate cyclase](/proteins/adenylyl-cyclase), reducing [cAMP](/mechanisms/camp-signaling-neurodegeneration) production and hyperpolarizing neurons through [GIRK channels](/proteins/girk-protein).
Custom variants: Modified versions like hM4Di-[Kir2.1](/proteins/kcnj2-protein) provide enhanced inhibitory effects through direct potassium channel coupling.
Designer Drug Pharmacology
The most commonly used DREADD ligand is clozapine N-oxide (CNO), which is the active metabolite of clozapine. However, recent studies have identified more selective compounds:
Experimental Applications
Circuit Mapping
DREADDs are widely used for mapping neural circuits:
Retrograde tracing: Can be combined with [retrograde viruses](/technologies/viral-vectors-neurodegeneration) to map [connectivity](/mechanisms/brain-network-connectivity-psp)
Functional connectivity: Assess downstream effects of specific neuron [activation](/mechanisms/neuronal-activation-patterns)
Disconnection experiments: Temporarily inactivate [brain regions](/brain-regions/hippocampus) to test [connectivity](/mechanisms/brain-network-connectivity-psp)
Temporal Control
The temporal resolution of DREADD manipulation:
Onset: 30-120 minutes after CNO administration
Duration: 6-24 hours depending on compound and expression
Reversible: Effects dissipate as ligand clears
Limitations and Considerations
Pharmacokinetic Issues
CNO has poor [blood-brain barrier](/entities/blood-brain-barrier) penetration
Back-metabolism to clozapine can confound results
Variable efficacy across [brain regions](/brain-regions/thalamus)
Alternative Approaches
For researchers considering [DREADDs](/technologies/dreadds) vs. other methods:
Future Directions
Clinical translation: First-in-human trials using [chemogenetics](/technologies/chemogenetics) for [epilepsy](/diseases/temporal-lobe-epilepsy) treatment
[Gene therapy](/therapeutics/gene-therapy-neurodegeneration): [AAV](/therapeutics/aav-gene-therapy-neurodegeneration)-delivered DREADDs for long-term modulation
Combination therapies: DREADDs paired with [neuroimaging](/technologies/fmri-neurodegeneration) for closed-loop control
Application to [tauopathies](/mechanisms/tauopathies) and [synucleinopathies](/mechanisms/synucleinopathies)
Background
The study of Designer Receptors Exclusively Activated By Designer Drugs (Dreadd) Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.